Al Hammadi’s unit seeks regulatory approval on Tadawul listing

07/12/2025 Argaam
Al Hammadi’s unit, Sudair Pharma, submits its IPO and listing applications to Saudi regulators

Al Hammadi’s unit, Sudair Pharma, submits its IPO and listing applications to Saudi regulators

Al Hammadi Holding Co. said its subsidiary, Sudair Pharmaceutical Co. (Sudair Pharma), submitted an application to the Capital Market Authority (CMA) to offer its shares in an initial public offering (IPO) on the Main Market (TASI).

Sudair Pharma, in which Al Hammadi holds a 35% stake, also applied to list its shares on the Saudi Exchange (Tadawul) as part of completing the regulatory requirements for the offering, according to a statement to Tadawul.
Al Hammadi said it will disclose any developments in due course.
 

According to Argaam data, Sudair Pharma was founded in 2014 with share capital of SAR 173 million. It primarily manufactures cancer treatment medications.

 

Sudair Pharma began producing specialized oncology drugs in 2021 and has recently started manufacturing insulin. The company is also working on launching new medications targeting respiratory diseases.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.